• Immutep reported positive Phase I results for autoimmune drug candidate IMP761, presented in a late-breaking abstract at ACR Convergence 2026.
• A single infusion significantly suppressed T-cell-driven immune responses in healthy volunteers, with stronger effects at higher exposure.
• IMP761 was well tolerated across all seven dose levels, with no serious or severe adverse events reported.
• The drug’s pharmacokinetic profile supports dosing every four weeks; the ongoing multiple-dose study has shown no new safety signals.
• Multiple-dose results are expected in the first half of 2027 to guide dose selection for a potential Phase II program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611081734PRIMZONEFULLFEED9872954) on November 08, 2026, and is solely responsible for the information contained therein.